Using hiPSCs to investigate the protective mechanisms of the ApoEch mutation
Using hiPSCs to investigate the protective mechanisms of the ApoEch mutation
批准号:
10303436
负责人:
DAVID A BRAFMAN
金额:
$43.18万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-30 至 2024-08-31
关键词:
3-DimensionalAddressAllelesAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAlzheimer&aposs disease riskAmino AcidsAmyloid beta-ProteinAnimal ModelAnimalsApolipoprotein EAstrocytesBiochemicalBiomedical EngineeringCarrier ProteinsCell LineCellsCholesterolCholesterol HomeostasisCoculture TechniquesDNADNA Double Strand BreakDataDevelopmentDiseaseDisease ProgressionDisease modelDouble Strand Break RepairEngineeringEnsureEpigenetic ProcessFutureGenerationsGenesGeneticGenetic PolymorphismGenetic TranscriptionGenotypeGoldHeterozygoteHumanHuman EngineeringIndividualInvestigationKaryotypeLipoprotein (a)MediatingMethodsModelingModificationMolecularMutationNerve DegenerationNeurodegenerative DisordersOnset of illnessPhenotypePrimary Cell CulturesProbabilityRegulator GenesReporterReportingResearchRiskRisk FactorsSeriesSignal PathwaySignaling ProteinSystemTNFRSF10A geneTechnologyTestingTherapeutic InterventionVariantapolipoprotein E-3apolipoprotein E-4basedesignexperiencegenome editinggenome wide association studyinduced pluripotent stem cellmolecular targeted therapiesmutation carrierneuroprotectionnon-dementednovelpluripotencypresenilin-1protective effectrare variantrelating to nervous systemrepairedstem cell modelstem cellstargeted treatmenttau Proteinstau phosphorylationtranscriptometranscriptome sequencingtranslational impactuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Although the majority of AD patient are sporadic, genome-wide association studies and related approaches have
identified numerous genetic factors that modulate the risk of AD onset and progression. While the majority of
these risk factors are associated with increased AD risk, several variants have been identified that reduce the
risk of AD. As such, variation in Apolipoprotein E (ApoE), a cholesterol transport protein secreted primarily by
astrocytes in the CNS, has been identified as one the more powerful of these risk factors. ApoE has three
common alleles which differ with respect to two amino acid residues. Compared to the risk neutral ApoE3/3
genotype, each additional copy of the ApoE4 increases risk of AD, while the presence the APO2 allele is
protective. More recently, an additional rare variant of APOE—the ApoE Christchurch (ApoCh)—was identified
as potentially mitigating neurodegeneration in a PSEN1 mutation carrier. As such, understanding the protective
mechanisms of the ApoCh variant will have a significant effect on therapeutic interventions. We and others have
used hiPSC-based models, which are highly complementary to existing animal and primary cell culture models,
to study AD is a simplified and accessible system. As such, we will use our collective experience in stem cell
bioengineering, neurodegenerative disease modeling, and genome editing to elucidate the potential
mechanisms by which ApoEch mitigates AD risk. In the first aim, we will use our recently developed highly
efficient gene editing approach to introduce the ApoEch mutation into isogenic hiPSCs. In the second aim, we
will perform biochemical, molecular, and transcriptome analysis of neural cultures derived from these isogenic
lines to test the hypotheses that ApoEch exerts its protection effects through (i) modulation of Aβ processing,
secretion, and uptake and (ii) alteration in tau hyperphosphorylation and internalization. In addition, we will use
RNA-seq analysis to identify signaling pathways, gene regulatory networks, and transcriptional target that are
independently influenced by the presence of the ApoEch mutation and disease status. Overall, a better
understanding of the mechanism by which ApoEch enhances neuroprotection against AD will have a significant
translational impact on the design of therapeutic interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Acquisition of an Automated Tissue Processor for the ASU Shared Imaging Core Facility
-
批准号:10737175
-
项目类别:
-
资助金额:$5.97万
-
财政年份:2023
-
负责人:DAVID A BRAFMAN
-
依托单位:
BD FACSymphony S6 cell sorter
-
批准号:10425932
-
项目类别:
-
资助金额:$59.93万
-
财政年份:2022
-
负责人:DAVID A BRAFMAN
-
依托单位:
Elucidating the protective effects of the KL-VS variant using isogenic hiPSCs
-
批准号:10354135
-
项目类别:
-
资助金额:$43.18万
-
财政年份:2022
-
负责人:DAVID A BRAFMAN
-
依托单位:
Establishing Genotype-to-Phenotype Relationships Between Alzheimer’s Related BIN1 Variants
-
批准号:10525652
-
项目类别:
-
资助金额:$43.18万
-
财政年份:2022
-
负责人:DAVID A BRAFMAN
-
依托单位:
A Pluripotent Stem Cell-Based Model to Investigate the Mechanisms of TBI-Induced AD
-
批准号:9903188
-
项目类别:
-
资助金额:$19.02万
-
财政年份:2019
-
负责人:DAVID A BRAFMAN
-
依托单位:
Investigating the mechanisms of a multi-state model of Wnt signaling
-
批准号:9329785
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2017
-
负责人:DAVID A BRAFMAN
-
依托单位:
Investigating the mechanisms of a multi-state model of Wnt signaling
-
批准号:9900020
-
项目类别:
-
资助金额:$29.63万
-
财政年份:2017
-
负责人:DAVID A BRAFMAN
-
依托单位:
Synthetic substrates for the expansion and differentiation of hPSC-derived NPCs
-
批准号:9181880
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2016
-
负责人:DAVID A BRAFMAN
-
依托单位:
海外基金